A Multi-Epitope Protein for High-Performance Serodiagnosis of Chronic Chagas Disease in ELISA and Lateral Flow Platforms

Author:

Dias Evandro R.1234,Durans Andressa M.13ORCID,Succar Barbara B.13ORCID,Pinto Luiz André L. T.1ORCID,Lechuga Guilherme C.13ORCID,Miguez Mariana G.5ORCID,Figueira-Mansur Janaina5ORCID,Argondizzo Ana P. C.5ORCID,Bernardo Aline R.6,Diniz Rafaela L.6,Esteves Gabriela S.5,Silva Edimilson D.6,Morel Carlos M.1ORCID,Borges-Pereira José4,De-Simone Salvatore G.137ORCID,Junqueira Angela C. V.24,Provance David William13ORCID

Affiliation:

1. Center for Technological Development in Health, National Institute of Science and Technology for Innovation in Neglected Population Diseases, Oswald Cruz Foundation, Rio de Janeiro 21040-361, RJ, Brazil

2. Tropical Medicine Graduate Program (Stricto Sensu), Oswaldo Cruz Institute, Oswald Cruz Foundation, Rio de Janeiro 21040-361, RJ, Brazil

3. Laboratório de Epidemiologia e Sistemática Molecular, Oswaldo Cruz Institute, Oswald Cruz Foundation, Rio de Janeiro 21040-361, RJ, Brazil

4. Laboratório de Doenças Parasitarias, Oswaldo Cruz Institute, Oswald Cruz Foundation, Rio de Janeiro 21040-361, RJ, Brazil

5. Laboratório de Tecnologia Recombinante, Institute of Technology in Immunobiology, Oswald Cruz Foundation, Rio de Janeiro 21040-361, RJ, Brazil

6. Laboratório de Reativos em Diagnóstico, Institute of Technology in Immunobiology, Rio de Janeiro 21040-361, RJ, Brazil

7. Science and Biotechnology Graduate Program, Department of Molecular and Cellular Biology, Biology Institute, Fluminense Federal University, Niterói 24020-141, RJ, Brazil

Abstract

We developed a protein to rapidly and accurately diagnose Chagas disease, a life-threatening illness identified by the WHO as a critical worldwide public health risk. Limitations in present day serological tests are complicating the current health situation and contributing to most infected persons being unaware of their condition and therefore untreated. To improve diagnostic testing, we developed an immunological mimic of the etiological agent, Trypanosoma cruzi, by combining ten pathogen-specific epitopes within the beta-barrel protein structure of Thermal Green Protein. The resulting multi-epitope protein, DxCruziV3, displayed high specificity and sensitivity as the antibody capture reagent in an ELISA platform with an analytical sensitivity that exceeds WHO recommendations. Within an immunochromatographic platform, DxCruziV3 showed excellent performance for the point of application diagnosis in a region endemic for multiple diseases, the municipality of Barcelos in the state of Amazonas, Brazil. In total, 167 individuals were rapidly tested using whole blood from a finger stick. As recommended by the Brazilian Ministry of Health, venous blood samples were laboratory tested by conventional assays for comparison. Test results suggest utilizing DxCruziV3 in different assay platforms can confidently diagnose chronic infections by T. cruzi. Rapid and more accurate results will benefit everyone but will have the most noticeable impact in resource-limited rural areas where the disease is endemic.

Funder

Oswaldo Cruz Foundation

Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro

National Council for Scientific and Technological Development

CNPq Productivity Grant in Technological Development and Innovative Extension—DT

Coordination of Superior Level Staff Improvement CAPES

Brazilian Council for Scientific Research

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3